Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Colombia, Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Colombia 2020 Forum is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Colombia and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speakers
Antonio Eduardo Sánchez García
CANIFARMA, Mexico
VP of Public Policies for Devices
Gabriela Posada
GSK, Mexico
Regulatory Affairs Director
Manuela Arboleda Montoya
PiSA Farmacéutica, Mexico
Business Development & Portfolio Management Director
Latam Biosimilars’s Insight. Panel Industry Leaders
Edgar Mauricio Rubio
Indukern, Colombia
Pharmaceutical & Animal Health Division Manager
Eduardo Cioppi
mAbxience, Argentina
Regional Director – Latin America
Jaime Uribe
PROBIOMED, Mexico
CEO